These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Entinostat as a combinatorial therapeutic for rhabdomyosarcoma. Chauhan S; Lian E; Habib I; Liu Q; Anders NM; Bugg MM; Federman NC; Reid JM; Stewart CF; Cates T; Michalek JE; Keller C Sci Rep; 2024 Aug; 14(1):18936. PubMed ID: 39147820 [TBL] [Abstract][Full Text] [Related]
45. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701 [TBL] [Abstract][Full Text] [Related]
46. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850 [TBL] [Abstract][Full Text] [Related]
47. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758 [TBL] [Abstract][Full Text] [Related]
48. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Kutko MC; Glick RD; Butler LM; Coffey DC; Rifkind RA; Marks PA; Richon VM; LaQuaglia MP Clin Cancer Res; 2003 Nov; 9(15):5749-55. PubMed ID: 14654560 [TBL] [Abstract][Full Text] [Related]
50. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent. Shen J; Hong Y; Zhao Q; Zhang JL Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112 [TBL] [Abstract][Full Text] [Related]
51. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report. Kusaczuk M; Krętowski R; Stypułkowska A; Cechowska-Pasko M Invest New Drugs; 2016 Oct; 34(5):552-64. PubMed ID: 27468826 [TBL] [Abstract][Full Text] [Related]
52. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
53. A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Ong PS; Wang L; Chia DM; Seah JY; Kong LR; Thuya WL; Chinnathambi A; Lau JY; Wong AL; Yong WP; Yang D; Ho PC; Sethi G; Goh BC Cancer Lett; 2016 Oct; 381(1):49-57. PubMed ID: 27461583 [TBL] [Abstract][Full Text] [Related]
54. CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma. Phelps MP; Bailey JN; Vleeshouwer-Neumann T; Chen EY Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15090-15095. PubMed ID: 27956629 [TBL] [Abstract][Full Text] [Related]
55. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300 [TBL] [Abstract][Full Text] [Related]
56. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307 [TBL] [Abstract][Full Text] [Related]
57. Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors. Kasiappan R; Jutooru I; Mohankumar K; Karki K; Lacey A; Safe S Mol Cancer Res; 2019 Mar; 17(3):794-805. PubMed ID: 30610105 [TBL] [Abstract][Full Text] [Related]
58. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449 [TBL] [Abstract][Full Text] [Related]
59. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis. Hamam HJ; Palaniyar N Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537 [TBL] [Abstract][Full Text] [Related]